Genmab A/S is to take over the Dutch company Merus NV for $8 billion in one of the largest European biotech transactions to date, giving it new tools for treating a host of cancers. Merus has a portfolio of bispecific and trispecific antibodies which are recombinant molecules that bind to one or more targets at the same time. The company has one marketed product, Bizengri (zenocutuzumab), which has been approved for non-small cell lung and pancreatic cancers, and a second, petosemtamab, which is in development for head and neck and colorectal cancers.
